SCHEMBL4399401

SCHEMBL4399401

O=C1CCC(NCc2cccc(OC(F)(F)F)c2)C(=O)N1

nearest known ligand 0.51

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 13/20 0.51
DDB1 Q16531 12/20 0.51
CARM1 Q86X55 2/20 0.47
PRMT6 Q96LA8 2/20 0.47
KIF11 P52732 1/20 0.43
MAPK14 Q16539 1/20 0.42
DAO P14920 1/20 0.41
KDM5A P29375 1/20 0.41
KDM4C Q9H3R0 1/20 0.41
KDM5B Q9UGL1 1/20 0.41
CHRM3 P20309 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4389136 0.86 CRBN (0.52) CRBNDDB1
SCHEMBL4390844 0.85 ALDH1A1 (0.55) CRBNDDB1
SCHEMBL6718553 0.82 CRBN (0.50) CRBNDDB1CARM1PRMT6
SCHEMBL4391390 0.81 CRBN (0.52) CRBNDDB1
SCHEMBL4399406 0.78 CRBN (0.52) CRBNDDB1
SCHEMBL4389143 0.78 CRBN (0.52) CRBNDDB1CARM1PRMT6
SCHEMBL6738737 0.78 CRBN (0.52) CRBNDDB1CARM1PRMT6
SCHEMBL4393897 0.78 CRBN (0.64) CRBNDDB1
SCHEMBL19370861 0.77 CRBN (0.60) CRBNDDB1
SCHEMBL4396934 0.77 CRBN (0.60) CRBNDDB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1252144-B1 SUBSTITUTED GLUTARIMIDES AND USE THEREOF IL-12 PRODUCTION INHIBITORS GRUENENTHAL GMBH (DE) 2009-12-09 EP disclosed
US-20040048859-A1 Substituted glutarimides and their use as inhibitors of IL-12 production GRUENENTHAL GMBH (DE) 2004-03-11 US disclosed
US-6656937-B2 Immunology moderators; interleukin antagonist; anticancer agents GRUENENTHAL, GMBH (DE) 2003-12-02 US disclosed
US-20030064987-A1 Substituted glutarimides and their use as inhibitors of IL-12 production GRUENENTHAL GMBH 2003-04-03 US disclosed
EP-1252144-A1 SUBSTITUTED GLUTARIMIDES AND USE THEREOF IL-12 PRODUCTION INHIBITORS Grünenthal GmbH (DE) 2002-10-30 EP disclosed
WO-2001053261-A1 SUBSTITUTED GLUTARIMIDES AND USE THEREOF IL-12 PRODUCTION INHIBITORS Grünenthal GmbH (DE) 2001-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040048859-A1 Substituted glutarimides and their use as inhibitors of IL-12 production GCDH, IL4I1, IL2 CRBN 949/4885DDB1 2435/4885CARM1 2941/4885
US-20030064987-A1 Substituted glutarimides and their use as inhibitors of IL-12 production GCDH, IL4I1, IL2 CRBN 949/4885DDB1 2435/4885CARM1 2941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.